Leap Financial Statements From 2010 to 2025

Stocks . USA . 
Stock . Leap Therapeutics
LPTX Stock  USD 0.31  0.01  3.13%   
Leap Therapeutics' financial statements offer valuable quarterly and annual insights to potential investors, highlighting the company's current and historical financial position, overall management performance, and changes in financial standing over time. Key fundamentals influencing Leap Therapeutics' valuation are provided below:
Gross Profit
1.5 M
Market Capitalization
12.7 M
Enterprise Value Revenue
1.8965
Revenue
375 K
Earnings Share
(1.67)
We have found one hundred twenty available fundamental ratios for Leap Therapeutics, which can be analyzed and compared to other ratios and to its peers in the industry. All investors should make sure to check all of Leap Therapeutics last-minute market performance against the performance between 2010 and 2025 to make sure the company can sustain itself down the road. Enterprise Value is likely to rise to about 68.4 M in 2025, whereas Market Cap is likely to drop slightly above 77.1 M in 2025.
Check Leap Therapeutics financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Leap Therapeutics' main balance sheet or income statement drivers, such as Depreciation And Amortization of 4.8 K, Interest Expense of 4.3 K or Selling General Administrative of 9.1 M, as well as many indicators such as Price To Sales Ratio of 110, Dividend Yield of 0.0024 or PTB Ratio of 1.56. Leap financial statements analysis is a perfect complement when working with Leap Therapeutics Valuation or Volatility modules.
  
Build AI portfolio with Leap Stock
Check out the analysis of Leap Therapeutics Correlation against competitors.
For more information on how to buy Leap Stock please use our How to Invest in Leap Therapeutics guide.

Leap Therapeutics Balance Sheet

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Total Assets45.9 M49.1 M38.9 M
Slightly volatile
Total Current Liabilities10.1 M14.1 M8.3 M
Slightly volatile
Property Plant And Equipment Net432.1 K301.3 K386.5 K
Pretty Stable
Accounts Payable3.5 M4.7 M2.8 M
Slightly volatile
Cash39.2 M47.2 M33.3 M
Slightly volatile
Non Current Assets Total1.8 M1.1 M1.7 M
Very volatile
Non Currrent Assets Other1.2 M823 K1.1 M
Slightly volatile
Cash And Short Term Investments42.7 M47.2 M36.2 M
Slightly volatile
Net Receivables1 M704 K827.4 K
Slightly volatile
Common Stock Total Equity106.3 K101.2 K47.9 K
Slightly volatile
Common Stock Shares Outstanding39.4 M37.6 M8.4 M
Slightly volatile
Liabilities And Stockholders Equity45.9 M49.1 M38.9 M
Slightly volatile
Other Current Assets81.7 K86 K269.2 K
Slightly volatile
Total Liabilities9.3 M14.1 M8 M
Slightly volatile
Property Plant And Equipment Gross470 K488 K414.4 K
Slightly volatile
Total Current Assets44 M48 M37.3 M
Slightly volatile
Other Assets1.5 M2 M1.1 M
Slightly volatile
Property Plant Equipment832 K792.4 K412.3 K
Slightly volatile
Short and Long Term Debt Total252.7 K266 K3.4 M
Pretty Stable
Capital Surpluse448.8 M427.4 M172.5 M
Slightly volatile
Other Liabilities174.4 K183.6 K6.2 M
Slightly volatile
Deferred Long Term Asset Charges112.8 K111.6 K139.5 K
Slightly volatile
Capital Stock55 K38 K32.8 K
Slightly volatile
Capital Lease Obligations433.7 K266 K807.5 K
Slightly volatile

Leap Therapeutics Income Statement

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Depreciation And Amortization4.8 K5 K418.2 K
Slightly volatile
Selling General Administrative9.1 M12.8 M7.5 M
Slightly volatile
Other Operating Expenses105.1 M100.1 M38.9 M
Slightly volatile
Research Development31 M57.2 M25.7 M
Slightly volatile
Total Operating Expenses39.8 M70.1 M32.9 M
Slightly volatile
Interest Income3.3 M3.1 M797 K
Slightly volatile
Preferred Stock And Other Adjustments338.8 K427.8 K309.4 K
Slightly volatile
Reconciled Depreciation4.8 K5 K36.5 K
Slightly volatile
Extraordinary Items9 M10.2 M11.1 M
Slightly volatile
Selling And Marketing Expenses341.6 K384.3 K419 K
Slightly volatile

Leap Therapeutics Cash Flow Statement

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Stock Based Compensation3.5 M5.5 M2.8 M
Slightly volatile
Begin Period Cash Flow74.2 M70.6 M31.4 M
Slightly volatile
Depreciation4.8 K5 K249.4 K
Slightly volatile
End Period Cash Flow39.2 M47.2 M33.3 M
Slightly volatile
Net Borrowings819.4 K862.5 K3.3 M
Pretty Stable

Financial Ratios

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Price To Sales Ratio110167113
Slightly volatile
Dividend Yield0.00240.00250.0097
Slightly volatile
Days Sales Outstanding27326099.8229
Slightly volatile
Stock Based Compensation To Revenue1.622.091.8666
Slightly volatile
Capex To Depreciation1.141.911.5039
Slightly volatile
EV To Sales65.598.1868.2522
Slightly volatile
Inventory Turnover0.660.750.8173
Slightly volatile
Payables Turnover0.04660.05940.0405
Slightly volatile
Sales General And Administrative To Revenue5.436.466.4962
Pretty Stable
Research And Ddevelopement To Revenue14.0219.315.463
Slightly volatile
Cash Per Share1.21.258313.6496
Slightly volatile
Days Payables Outstanding6 K6.4 K13.8 K
Slightly volatile
Income Quality0.670.89260.8489
Pretty Stable
Intangibles To Total Assets0.00620.00650.0214
Slightly volatile
Current Ratio3.243.41287.9723
Slightly volatile
Receivables Turnover1.381.4514.5401
Slightly volatile
Capex Per Share0.04840.05090.0916
Slightly volatile
Revenue Per Share0.230.20.2335
Slightly volatile
Interest Debt Per Share0.00670.00713.4175
Pretty Stable
Debt To Assets0.00510.00540.3631
Pretty Stable
Operating Cycle27326099.8229
Slightly volatile
Days Of Payables Outstanding6 K6.4 K13.8 K
Slightly volatile
Ebt Per Ebit1.080.95590.9768
Very volatile
Quick Ratio3.243.41287.9723
Slightly volatile
Net Income Per E B T1.11.161.0189
Slightly volatile
Cash Ratio3.193.35676.5512
Slightly volatile
Days Of Sales Outstanding27326099.8229
Slightly volatile
Free Cash Flow Operating Cash Flow Ratio1.111.151.023
Slightly volatile
Fixed Asset Turnover2.222.732.6166
Slightly volatile
Debt Ratio0.00510.00540.3631
Pretty Stable
Price Sales Ratio110167113
Slightly volatile
Asset Turnover0.02220.01460.0237
Slightly volatile

Leap Therapeutics Valuation Data

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Market Cap77.1 M108.1 M86 M
Pretty Stable

Leap Fundamental Market Drivers

Cash And Short Term Investments47.2 M

Leap Upcoming Events

22nd of March 2024
Upcoming Quarterly Report
View
20th of May 2024
Next Financial Report
View
31st of December 2023
Next Fiscal Quarter End
View
22nd of March 2024
Next Fiscal Year End
View
30th of September 2023
Last Quarter Report
View
31st of December 2022
Last Financial Announcement
View

About Leap Therapeutics Financial Statements

Leap Therapeutics investors use historical fundamental indicators, such as Leap Therapeutics' revenue or net income, to determine how well the company is positioned to perform in the future. Understanding over-time patterns can help investors decide on long-term investments in Leap Therapeutics. Please read more on our technical analysis and fundamental analysis pages.
Last ReportedProjected for Next Year
Current Deferred Revenue1.7 M1.8 M
Cost Of Revenue491.1 K515.6 K
Stock Based Compensation To Revenue 2.09  1.62 
Sales General And Administrative To Revenue 6.46  5.43 
Research And Ddevelopement To Revenue 19.30  14.02 
Revenue Per Share 0.20  0.23 
Ebit Per Revenue(31.76)(33.35)

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.
USOICredit Suisse X Links
ULTYTidal Trust II
CONYYieldMax N Option

Additional Tools for Leap Stock Analysis

When running Leap Therapeutics' price analysis, check to measure Leap Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Leap Therapeutics is operating at the current time. Most of Leap Therapeutics' value examination focuses on studying past and present price action to predict the probability of Leap Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Leap Therapeutics' price. Additionally, you may evaluate how the addition of Leap Therapeutics to your portfolios can decrease your overall portfolio volatility.
Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions
 
Feedback Blog
Made with optimal in San Francisco
2025 Macroaxis LLC
COMMON DESTINATIONS
MAIN CATEGORIES
COMPANY